Ascendis Pharma, Novo Nordisk Partner For Development, Commercialization Of TransCon Technology-Based Products In Metabolic, Cardiovascular Diseases; Ascendis To Be Eligible To Receive Payments Of Up To $285M For Lead Program
Ascendis Pharma, Novo Nordisk Partner For Development, Commercialization Of TransCon Technology-Based Products In Metabolic, Cardiovascular Diseases; Ascendis To Be Eligible To Receive Payments Of Up To $285M For Lead Program
The closing of this transaction is subject to receipt of applicable regulatory approvals and the parties are seeking to close before the end of 2024.Ascendis has granted Novo Nordisk A/S an exclusive worldwide license to the TransCon technology platform to develop, manufacture and commercialize Novo Nordisk proprietary products in metabolic diseases (including obesity and type 2 diabetes) and a product-by-product exclusive license in cardiovascular diseases.
Ascendis已經授予Novo Nordisk A/S獨家全球許可使用TransCon技術平台，用於開發、製造和商業化Novo Nordisk的專有產品，涵蓋代謝性疾病（包括肥胖和2型糖尿病）以及心血管疾病的一攬子專有許可。
In exchange for the license, Ascendis will be eligible to receive total payments of up to $285 million in upfront, development, and regulatory milestone payments for the lead program.
作爲許可的交換條件，Ascendis有權獲得高達28500萬美元的初始、研發和監管里程碑付款，用於主導項目。
In addition, Ascendis will be eligible to receive sales-based milestone payments and tiered royalties on global net sales. For each additional metabolic or cardiovascular disease product candidate, Ascendis will be eligible to receive payments of up to $77.5 million in development and regulatory milestone payments, plus sales-based milestone payments and tiered royalties on global net sales.
此外，Ascendis有權獲得基於銷售的里程碑付款，並按照全球淨銷售額支付分階段的特許權使用費。對於每一個額外的代謝性或心血管疾病產品候選者，Ascendis有權獲得高達7750萬美元的研發和監管里程碑付款，以及基於銷售的里程碑付款和按照全球淨銷售額支付分階段的特許權使用費。
The closing of this transaction is subject to receipt of applicable regulatory approvals and the parties are seeking to close before the end of 2024.
本交易的完成取決於獲得適用的監管批准，並且各方正尋求在2024年年底之前完成交易。
譯文內容由第三人軟體翻譯。
